Imitab 400 MG (Imatinib) Tablets

Introduction

Imitab 400 mg (Imatinib) Tablet is a revolutionary tyrosine kinase inhibitor designed to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), gastrointestinal stromal tumors (GIST), and rare cancers like aggressive systemic mastocytosis (ASM) and dermatofibrosarcoma protuberans (DFSP). This targeted therapy disrupts cancer progression by inhibiting abnormal kinase activity, offering high efficacy with manageable side effects.

Key Benefits & Mechanism of Action

Imitab 400 mg (Imatinib) Tablet targets critical kinases to halt cancer growth:

bcr-abl Inhibition: Blocks the Philadelphia chromosome-driven tyrosine kinase in CML, inducing apoptosis in leukemia cells.
PDGFR & c-kit Suppression: Inhibits platelet-derived growth factor receptors (PDGFR) and c-kit mutations in GIST, preventing tumor proliferation.
Dual Action: Combines antiproliferative and antiangiogenic effects to disrupt cancer cell survival.

Indications

Imitab 400 mg (Imatinib) Tablet is approved for:

Ph+ CML: Newly diagnosed chronic phase (CP), accelerated phase (AP), blast crisis (BC), and post-interferon failure.
Ph+ Acute Lymphoblastic Leukemia (ALL): Relapsed/refractory cases.
GIST: Kit (CD117)-positive unresectable/metastatic tumors.
Rare Cancers:
- Myelodysplastic/myeloproliferative diseases (MDS/MPD) with PDGFR mutations.
- Aggressive systemic mastocytosis (ASM) without D816V c-Kit mutation.
- Hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFRα fusion.
- Dermatofibrosarcoma protuberans (DFSP).

Dosage & Administration

Adults with Ph+ CML CP: 400 mg once daily with food.

Ph+ CML AP/BC: 600 mg/day.
GIST/DFSP: 400–800 mg/day (split into twice-daily dosing for 800 mg).
Pediatric Ph+ CML: 260–340 mg/m²/day.
Hepatic Impairment: Adjust to 300–400 mg/day based on severity.

Administration Guidelines

Take with a meal and water to reduce gastrointestinal irritation.
Dissolve tablets in water/apple juice for patients with swallowing difficulties.

Pharmacokinetics

Absorption: 98% bioavailability; peak concentration in 2–4 hours.
Metabolism: Primarily via CYP3A4; active metabolite (CGP74588) has similar efficacy.
Excretion: 81% eliminated in feces (68%) and urine (13%) over 7 days.
Half-Life: Imatinib: 18 hours; metabolite: 40 hours.
Protein Binding: 95% (albumin and α1-acid glycoprotein).

Side Effects

Common Reactions

Fluid Retention: Edema (periorbital, leg swelling).
Gastrointestinal: Nausea (50%), vomiting, diarrhea (45%), abdominal pain.
Musculoskeletal: Muscle cramps (35%), pain.
Dermatologic: Rash (30%), fatigue.

Serious Adverse Events

Hepatotoxicity: Monitor liver enzymes monthly.
Cytopenias: Anemia, neutropenia, thrombocytopenia (check blood counts weekly initially).
Cardiac Issues: Congestive heart failure (monitor high-risk patients).
GI Perforation: Rare but life-threatening.

Manufacturer & Supplier Overview

Manufacturer: Eskayef Pharmaceuticals Ltd., a flagship enterprise of Bangladesh’s Transcom Group, has been a pioneer in oncology innovation since 1990. Their state-of-the-art, WHO-GMP-certified facilities ensure Imitab 400 mg (Imatinib) Tablet adheres to global safety and efficacy standards. With a legacy of delivering affordable therapies, Eskayef serves patients across Asia, Africa, and Europe. For more details, visit www.skfbd.com.

Supplier: Onco Solution is a global leader in oncology medicine distribution, committed to bridging gaps in cancer care. They ensure Imitab 400 mg (Imatinib) Tablet reaches healthcare providers and patients in over 50 countries through competitive bulk procurement, reliable logistics, and clinical support resources. Clinicians can access dosing guidelines and expert consultations via www.oncosolution.com.

Warnings & Precautions

Pregnancy/Lactation: Contraindicated; may cause fetal harm. Avoid breastfeeding.
Edema: Manage with diuretics; weigh patients regularly.
Drug Interactions: Avoid CYP3A4 inducers (e.g., phenytoin) and inhibitors (e.g., erythromycin).
Hepatotoxicity: Assess liver function before and during therapy.
Hypothyroidism: Monitor TSH in thyroidectomy patients on levothyroxine.

Drug Interactions

CYP3A4 Inhibitors (e.g., Ketoconazole): Increase imatinib exposure.
CYP3A4 Inducers (e.g., Rifampicin): Reduce efficacy by 30–40%.
Warfarin: Use alternatives due to altered INR.
Acetaminophen: Risk of liver toxicity; avoid prolonged use.

Overdose Management

Symptoms: Elevated creatinine, ascites, muscle cramps (reported at 1,200–1,600 mg/day).
Treatment: Supportive care; temporary interruption until toxicity resolves.

Storage & Handling

Conditions: Store below 30°C in original packaging, away from moisture and light.
Keep Out of Reach of Children.

Conclusion

Imitab 400 mg (Imatinib) Tablet remains a cornerstone in targeted cancer therapy, offering hope for patients with Ph+ CML, GIST, and rare malignancies. Trust Eskayef Pharmaceuticals Ltd. for uncompromised quality and Onco Solution for seamless global access. For orders or clinical guidance, contact Onco Solution today.